Moderna, Inc. (NASDAQ:MRNA) Stock Has Average Target Price of $113.75

Key Points

• Analyst sentiment is mixed: 15 of 25 brokerages rate Moderna “Hold,” while six recommend “Buy” and four “Sell.” The average one-year price target is $113.75.
• Moderna beat quarterly estimates, reporting EPS of $0.38 versus expectations of a $1.10 loss and revenue of $1.31 billion, up 29.2% year over year.
• Growth prospects remain uncertain: Oncology and its personalized cancer vaccine offer potential longer-term growth, but investors are weighing about $4 billion in planned 2027 cash costs and concerns that the 2026 revenue outlook may disappoint.

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) have earned an average recommendation of "Hold" from the twenty-five brokerages that are currently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $113.75.

MRNA has been the subject of a number of analyst reports. Barclays boosted their price target on Moderna from $48.00 to $125.00 and gave the company an "equal weight" rating in a report on Monday, August 24th. Evercore upped their price objective on shares of Moderna from $50.00 to $80.00 in a research report on Thursday, October 8th. Bradesco Corretora upgraded Moderna to an "outperform" rating in a research note on Friday, August 28th. Loop Capital set a $135.00 target price on Moderna in a research report on Wednesday, August 19th. Finally, The Goldman Sachs Group raised their price target on shares of Moderna from $137.00 to $195.00 and gave the company a "neutral" rating in a research note on Monday, November 9th.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 34,836 shares of Moderna stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares in the company, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the business's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider directly owned 74,129 shares in the company, valued at $10,374,353.55. This trade represents a 4.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 197,251 shares of company stock valued at $33,875,904. Corporate insiders own 10.80% of the company's stock.

Hedge Funds Weigh In On Moderna

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Moderna in the second quarter valued at $2,142,877,000. Theleme Partners LLP purchased a new stake in shares of Moderna in the 2nd quarter valued at approximately $564,272,000. Merck & Co. Inc. purchased a new position in Moderna in the second quarter valued at $161,642,545. Bamco Inc. NY purchased a new position in shares of Moderna in the 2nd quarter valued at about $139,317,000. Finally, Bank of New York Mellon Corp purchased a new stake in Moderna during the second quarter worth approximately $119,168,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Moderna

Here are a few of the latest stories about MRNA:

• Positive Sentiment: The company highlighted progress in its oncology pipeline, including its personalized cancer vaccine, positioning cancer treatments as a potential longer-term growth driver. Article
• Neutral Sentiment: Moderna is scheduled to join the MSCI World Index in November, which could broaden its investor reach. It also reported peer-reviewed real-world data on its mNEXSPIKE COVID-19 vaccine in older adults; the reports provided limited detail on the potential commercial impact. Article
• Negative Sentiment: Investors are concerned about roughly $4 billion in planned 2027 cash costs, much of it tied to pipeline investment, while visibility into future revenue growth remains limited. Coverage also noted that the 2026 revenue outlook may fall short of analyst expectations, tempering the more optimistic growth forecast. Article

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $223.37 on Friday. The company has a market cap of $90.38 billion, a PE ratio of -31.46 and a beta of 1.16. Moderna has a twelve month low of $22.28 and a twelve month high of $280.80. The company's 50 day moving average is $201.67 and its 200 day moving average is $96.41. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.10) by $1.48. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm's quarterly revenue was up 29.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.51) earnings per share. On average, sell-side analysts forecast that Moderna will post -5.34 EPS for the current year.

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company's commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.